🔎 Trials Near Me

Home › IGA Glomerulonephritis › California

IGA Glomerulonephritis clinical trials in California

8 studies for IGA Glomerulonephritis are looking for participants at sites in California.

Cities in California

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  • Kidney & Hypertension Center - Apple Valley, Apple Valley
  • Scripps Green Hospital, Carlsbad
  • UCLA Health David Geffen School of Medicine, Los Angeles
  • and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06935357

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

  • Jade Clinical Site, Chula Vista
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Sep 25, 2026 · NCT07541287

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

  • Valley Childrens Hospital, Madera
RecruitingPhase 3
Ages 2 to 18 · All sexes · Updated Sep 9, 2026 · NCT06994845

Study of WAL0921 in Patients With Glomerular Kidney Diseases

  • Academic Medical Research Institute, Los Angeles
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 3, 2026 · NCT06466135

Study of Ravulizumab in Pediatric Participants With Primary IgAN

  • Research Site, Palo Alto
RecruitingPhase 3
Ages 2 to 18 · All sexes · Updated Jul 30, 2026 · NCT07024563

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

  • UCLA Medical Center, Los Angeles
RecruitingPhase 2
Ages 18 to 99 · All sexes · Updated Jul 29, 2026 · NCT06797518

Atacicept in Multiple Glomerular Diseases

  • Vera Therapeutics, Brisbane
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 26, 2026 · NCT06983028

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

  • Cedars-Sinai Medical Center, Los Angeles
RecruitingPhase 2
Ages 1 to 17 · All sexes · Updated May 12, 2026 · NCT05003986

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.